Adaptive Biotechnologies Toekomstige groei
Future criteriumcontroles 1/6
Adaptive Biotechnologies zal naar verwachting groeien in winst en omzet met respectievelijk 24.8% en 18.5% per jaar. De winst per aandeel zal naar verwachting groeien met 26.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -88.8% zijn.
Belangrijke informatie
24.8%
Groei van de winst
26.1%
Groei van de winst per aandeel
| Life Sciences winstgroei | 18.3% |
| Inkomstengroei | 18.5% |
| Toekomstig rendement op eigen vermogen | -88.8% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 18 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?
Nov 01
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher
Oct 05Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk
Jul 12Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth
Jan 09Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 264 | -102 | -29 | -96 | 6 |
| 12/31/2025 | 211 | -140 | -57 | -127 | 8 |
| 12/31/2024 | 178 | -164 | -73 | -122 | 8 |
| 9/30/2024 | 177 | -195 | -115 | -110 | N/A |
| 6/30/2024 | 169 | -213 | -137 | -129 | N/A |
| 3/31/2024 | 175 | -215 | -145 | -136 | N/A |
| 12/31/2023 | 170 | -225 | -167 | -156 | N/A |
| 9/30/2023 | 180 | -196 | -171 | -159 | N/A |
| 6/30/2023 | 190 | -191 | -170 | -155 | N/A |
| 3/31/2023 | 184 | -195 | -195 | -179 | N/A |
| 12/31/2022 | 185 | -200 | -200 | -184 | N/A |
| 9/30/2022 | 168 | -221 | -231 | -208 | N/A |
| 6/30/2022 | 160 | -232 | -241 | -209 | N/A |
| 3/31/2022 | 155 | -229 | -248 | -199 | N/A |
| 12/31/2021 | 154 | -207 | -254 | -193 | N/A |
| 9/30/2021 | 147 | -190 | -241 | -179 | N/A |
| 6/30/2021 | 133 | -171 | -234 | -182 | N/A |
| 3/31/2021 | 116 | -155 | -208 | -176 | N/A |
| 12/31/2020 | 98 | -146 | -168 | -150 | N/A |
| 9/30/2020 | 92 | -122 | -148 | -137 | N/A |
| 6/30/2020 | 92 | -99 | -131 | -120 | N/A |
| 3/31/2020 | 93 | -82 | -115 | -105 | N/A |
| 12/31/2019 | 85 | -70 | 194 | 205 | N/A |
| 9/30/2019 | 78 | -62 | 215 | 227 | N/A |
| 6/30/2019 | 69 | -56 | 235 | 245 | N/A |
| 3/31/2019 | 59 | -53 | 243 | 252 | N/A |
| 12/31/2018 | 56 | -46 | -39 | -32 | N/A |
| 12/31/2017 | 38 | -43 | N/A | -35 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat ADPT de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat ADPT de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat ADPT de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van ADPT ( 18.5% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).
Hoge groei-inkomsten: De omzet van ADPT ( 18.5% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat ADPT binnen 3 jaar verliesgevend zal zijn.